IN THE UNESD STATES PATENT AND TRADEMARK

Group Art Unit

Examiner:

Atty. Dkt.

1638 Unknown

0275850 M#

T 7060C

Client Ref

PATENI APPLIC

Inventor(s): FRENKEN et al. 09 Appin. No.:

Washington, D.C. 20231

Series Code ↑ December 18, 2000

737,476 Serial No. 个

Hon. Commissioner of Patents

JUN 0 5 2001

:Appin. Title:

PRODUCTION OF ANTIBODIES

Sir:

Filed:

### SUBMISSION UNDER 37 CFR \$\$ 1.821 ET SEQ.

June 5, 2001 Date:

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

# FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim					•		
A. NOT made For B & C  B. Withdrawn See Required	Claims remaining after	Highest number P previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code
C. made herewith Separate Paper	amendment					l Lee	Lg/Sm
D. made previously (Pat-256)							
2. Total Effective Claims	16	**minus	20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	2	***minus	3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multip							
time (leave blank if this is a reissue a	+ \$270/\$135 =	+ \$0	104/204				
	5. Original due Date: May 5, 2001 NONE NONE 110/\$55						4 4 2 5
6. Petition is hereby made to extend		1	115/215 116/216				
date to cover the date this response i	+ \$110	* * *	117/217				
requisite fee is attached	10	***	118/218				
(Usable	4.1		128/228				
(Usable <u>on</u>	4 - 3 - 4						
7. Enter any previous extension fee p	n						
8.	+ \$110	27					
9. If Terminal Disclaimer attached,	+ \$110/\$55	+ \$0	148/248				
10. If IDS attached requires Official F	+ \$180	+ \$0	126				
or if Rule 97(d) Request							126
11. After-Final Request Fee per rules	+ \$710/355	+ \$0	146/246				
12. No. of additional inventions for ex	x \$710/355 ea + \$710/355	+ \$0	149/249				
13. Request for Continued Examinati	+ \$0	1179/1279					
14. Petition fee for	+ \$0	<u> </u>					
15.	\$110						

<sup>16. \*</sup>If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

Our Deposit Account No. 03-3975) (Our Order No. 060113 0275850

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be itld, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Sig

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP Intellectual Property Group

B√ Atty: Paul N. Kokulis Reg. No. 16773

Fax: Tel:

(202) 822-0944

(202) 861-3503

Tel: (202) 861-3000 Atty/Sec: PNK/nlh

1100 New York Avenue, NW

Washington, DC 20005-3918

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

Document6

Ninth Floor

<sup>17. \*\*</sup>If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

<sup>18. \*\*\*</sup>If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

#### PATENT APPLICATION ED STATES PATENT AND TRADEMARK Group Art Unit 1638 Examiner: FRENKEN et al. Unknown Inventor(s): 737,476 Atty. Dkt. 0275850 T 7060C Appin. No.: 09 Series Code ↑ Client Ref Serial No. 1 M# Filed: December 18, 2000 Appln. Title: PRODUCTION OF ANTIBODIES Hon. Commissioner of Patents Washington, D.C. 20231 JUN 0 5 2001 Sir: SUBMISSION UNDER 37 CFR \$\$ 1.821 ET SEGE TRADE

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

Date:

June 5, 2001

## FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim								
A. NOT made For B & C B. Withdrawn See Required	Claims remaining after	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code	
C. made herewith Separate Paper	amendment	previously pala ioi					Lg/Sm	
D. made previously (Pat-256)								
	<u> </u>					1 22	100/000	
2. Total Effective Claims	16	**minus	20	0	x \$18/\$9 =	+ \$0	103/203	
3. Independent Claims	2	***minus	3	0	x \$80/\$40 =	+ \$0	102/202	
4. If amendment enters proper multi								
time (leave <u>blank</u> if this is a <u>reissue</u>	+ \$270/\$135 =	+ \$0	104/204					
5. Original due Date: May 5, 200	1	☐ NONE				4		
6. Petition is hereby made to exter		00 S	115/215					
date to cover the date this response	+ \$110		116/216					
requisite fee is attached (3 mos)   \$890/\$445 =							117/217 118/218	
(Usat		App.	128/228					
(Usable <u>o</u>			120/220					
7. Enter any previous extension fee	- \$0	Aut.						
8.	+ \$110							
9. If Terminal Disclaimer attached,	+ \$110/\$55	+ \$0	148/248					
10. If IDS attached requires Official	+ \$180	+ \$0	126					
or if Rule 97(d) Request	+ \$180	+ \$0	126					
11. After-Final Request Fee per rule	+ \$710/355	+ \$0	146/246					
12. No. of additional inventions for e	x \$710/355 ea	+ \$0	149/249					
13. Request for Continued Examina	+ \$0	1179/1279						
14. Petition fee for	+ \$0							
15. TOTAL FEE ENCLOSED =							\$110	
u u u u u u u u u u u u u u u u u u u								

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

Our Deposit Account No. 03-3975) (Our Order No. 060113 0275850

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately

Pillsbury Winthrop LLP Intellectual Property Group Atty: Paul N. Kokulis

1100 New York Avenue, NW Ninth Floor

Washington, DC 20005-3918

Tel: (202) 861-3000 Atty/Sec: PNK/nlh

Sig:

Reg. No.

(202) 822-0944 (202) 861-3503

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

<sup>18. \*\*\*</sup>If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.







COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
TWW.USDIO.GOV

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/737,476

1100 New York Avenue, N.W. Washington, DC 20005-3918

12/18/2000

Leo G.J. Frenken

PM 275850 T7060C

**CONFIRMATION NO. 9341** 

**FORMALITIES LETTER** 

Cushman Darby & Cushman Intl. Prop. Group

Pillsbury Madison & Sutro L.L.P.

East Tower, Ninth Floor

\*OC000000005828279\*

Date Mailed: 03/05/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

M

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

00000052 09727476

PART 2 - COPY TO BE RETURNED WITH RESPONSE